Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-04-29
1995-11-07
Jordan, Kimberly R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514303, 514394, 514397, 514417, 5142235, A61K 3154, A61K 3144, A61K 3141, A61K 31415, A61K 3140
Patent
active
054648548
ABSTRACT:
The method of treatment moderating, blocking and/or eliminating premenstrual syndrome embodies the intermittent administering of an AT1 antagonist to a female having menstrual cycles characterized predominately by during substantially the luteal phase inclusive of at least one and frequently by two or more affective and/or autonomic and/or somatic symptoms of substantially incapacitating severity(ies) proximately substantially prior to menses of a menstrual cycle. Losartan is an example of an AT1 inhibitor and is administered either orally or parenterally continuously to a female during her menstrual cycle's luteal phase.
REFERENCES:
patent: 4912096 (1990-03-01), Sudilovsky
patent: 4931430 (1990-06-01), Sudilovsky et al.
patent: 5246943 (1993-09-01), Blankley et al.
Conn's Current Therapy, 1992, pp. 1014-1017.
LandOfFree
Method of modifying ovarian hormone-regulated AT1 receptor activ does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of modifying ovarian hormone-regulated AT1 receptor activ, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of modifying ovarian hormone-regulated AT1 receptor activ will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-197550